Anti-tumor action of alkyl-lysophospholipids (Review).

Berdel We, Bausert Wr, U. Fink, +2

PubMed

Chemoprevention StrategyApoptosisCell DeathPhospholipid MetabolismTumor Biology +15

Early assessment of minimal residual disease in AML by flow cytometry during aplasia identifies patients at increased risk of relapse

Thomas Köhnke, Diane Sauter, Katharina Ringel, +15

Leukemia

Hematological MalignancyMedicineHematologyPathologyAplasia Identifies Patients +4

Inhibition by alkyl-lysophospholipids of tritiated thymidine uptake in cells of human malignant urologic tumors.

Berdel We, U. Fink, Boris Egger, +3

PubMed

Tumor BiologyUrologyOncologyConventional Cytostatic DrugsMedicine +9

Lack of correlation between cytotoxicity of agonists and antagonists of platelet activating factor [paf-acether] in neoplastic cells and modulation of [3H]-paf-acether binding to platelets from humans in vitro.

Berdel We, R. Korth, Andreas S. Reichert, +6

PubMed

Chemoprevention StrategyImmunologyPharmacotherapyTumor BiologyInflammation +14

Growth inhibition of malignant hypernephroma cells by autologous lysophospholipid incubated macrophages obtained by a new method.

Berdel We, U. Fink, Boris Egger, +3

PubMed

Pure MacrophagesImmunologyBlood CellPathologyCell Death +23

Platelet-activating factor-induced coronary constriction in the isolated perfused guinea pig heart and antagonistic effects of the PAF antagonist WEB 2086.

Felix Sb, A C Steger, Gert Baumann, +3

PubMed

Heart FailureCardiovascular PharmacologyPlatelet-activating FactorPharmacotherapyCardiovascular Function +16

Differential cytotoxicity of an ether lipid on lymphoma and bone marrow cells and its role in purging malignant lymphoid cells from remission bone marrow contaminated with tumor cells.

Dietzfelbinger Hf, Abigail Lang, D Oberberg, +2

PubMed

Different mechanisms of inhibition by alkyl-lysophospholipid and phorbol ester of granulocyte-macrophage colony-stimulating factor binding to human leukemic cell lines.

Mikio Shoji, Takeshi Fukuhara, Winton Ef, +2

PubMed

Matrix metalloproteinase/integrin interactions as target for anti-angiogenic treatment strategies.

Alexander Pfeifer, Steve Silletti, RM Mesters, +3

PubMed